Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Maribavir in Chinese Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Cidofovir or Foscarnet

NCT06439342 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06439342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06439342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Maribavir in Chinese Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Cidofovir or Foscarnet
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
December 16, 2024
Completion date
July 22, 2026
Enrollment
20 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus (cmv)